Highlights Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Market Closed - London S.E. Other stock markets 09:05:03 10/05/2024 pm IST			5-day change	1st Jan Change
3.15 ^GBX	+0.80%		+9.57%	+26.00%

07/05	Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	CI
03/04	Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abingdon Health buys IVDeology Holdings	08/05	AN
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL	07/05	CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line	27/03	AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M	27/03	MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58	27/03	MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024	27/03	CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	27/03	CI
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate	12/03	CI
Allergy Therapeutics forecasts revenue drop but trials going well	14/02	AN
Alliance Pharma appoints chair; FireAngel sales down	05/02	AN
Allergy Therapeutics resumes trading on AIM; annual revenue plunges	30/01	AN
Allergy Therapeutics amends facility, plans warrant issue	27/12	AN
EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens	16/12	AN
AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer	13/12	AN
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL	13/12	CI
Allergy Therapeutics in Advanced Talks for Potential Funding; Shares Drop	11/12	MT
Allergy Therapeutics stock falls on lower sales outlook	11/12	AN
Allergy Therapeutics plc Announces Interim Top Line Results from its Pivotal G306 Phase III Trial of Grass MATA MPL	14/11	CI
ZQ Raises Holding in Allergy Therapeutics to 65% After Offer Closure	10/11	MT
SkyGem to Launch Mandatory Cash Bid for Remaining Allergy Therapeutics Shares	16/23/16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allergy Therapeutics plc

Equities

AGY

GB00B02LCQ05

Highlights

Filters